Patients on DAPT for at least 6 months will be tested for platelet function testing with the P2Y12 VerifyNow assay at baseline. The patients will then undergo at least a 2-week course of Trimetazidine 35 mg/q12h, followed thereafter by platelet function testing.

Platelet Dysfunction Due to Drugs

Trimetazidine is a clinically effective antianginal agent that has no negative inotropic or vasodilator properties (6). It is presently clinically used throughout Europe and in >80 countries worldwide. It is a cytoprotective drug that normalizes metabolic disturbances in low-flow ischemia via several—not yet fully understood—mechanisms of action (7). The best-known mechanism of action is its capacity to inhibit β-oxidation of free fatty acid (FFA) (7).

Trimetazidine

The University of the West Indies

Trimetazidine as an Adjunct to Enhance Clopidogrel Response.

Trimetazidine as an Adjunct to Enhance Clopidogrel Response: The TRACER Study.

The investigators postulate that inhibition of platelet aggregation in response to Clopidogrel may be accentuated by Trimetazidine, i.e. Trimetazidine enhances Clopidogrel response.

All available data can be obtained by contacting the corresponding author.

The University of The West Indies

The study will be of a prospective, randomized, controlled, sequential trial design.

The Outcomes Assessor will be independent of the Clinical Research Associates, i.e. he/she will be analyzing the VerifyNow samples without knowledge of the intervention the patient has received.

antianginal/huvudvärk

Trimetazidine as an Adjunct to Enhance Clopidogrel Response.

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen